Rutger C.
- Country
- Belgium
- Department
- Hematology
Research Overview
- A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cells (GLPG5301; BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (RRMM)
- Long-term Safety Evaluation of BCN-CP01, 19CP02, and BCMACP03 in Patients with Relapsed/Refractory CLL, SLL, B-Cell NHL, or Multiple Myeloma
- Phase 3 Open-Label Study of Elranatamab vs. Elotuzumab, Pomalidomide, Dexamethasone, or Carfilzomib in Relapsed/Refractory Multiple Myeloma Post Anti-CD38 Therapy
Data & Insights
Has run more than one trial at 23 of 154 partner sites.
Specializations
Multiple Myeloma Treatment
This investigator specializes in multiple myeloma research, with particular emphasis on developing innovative therapeutic approaches for both newly diagnosed and relapsed/refractory cases.
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Transplant-Ineligible Multiple Myeloma
- Novel Therapeutic Combinations
The investigator explores various treatment modalities including CAR T-cell therapy and antibody-based treatments.
Immunotherapy Applications
The investigator's work encompasses advanced immunotherapeutic approaches in hematologic malignancies, particularly focusing on targeted therapies.
- Anti-BCMA CAR T-cell Therapy
- Monoclonal Antibody Treatments
- Point-of-Care Manufacturing
Their research includes evaluation of novel immunotherapy combinations and treatment optimization strategies.
Therapeutic Innovation
The investigator leads research in comparative therapeutic strategies, evaluating various drug combinations and treatment approaches.
- Novel Drug Combinations
- Treatment Response Assessment
- Safety and Efficacy Studies
Their work includes investigation of innovative treatment regimens for different patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.